Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Relapsed aggressive lymphomas are often treated with platinum-based chemotherapy (PBC) followed by an autologous stem cell transplant (ASCT). Response rates to PBC in patients with relapsed aggressive lymphomas are c. 60%, and non-responders have a dismal prognosis. Novel therapies for aggressive ly...

Full description

Saved in:
Bibliographic Details
Published in:Br J Haematol
Main Authors: Westin, Jason R., McLaughlin, Peter, Romaguera, Jorge, Hagemeister, Fredrick B., Pro, Barbara, Dang, Nam H., Samaniego, Felipe, Rodriguez, Maria A., Fayad, Luis, Oki, Yasuhiro, Fanale, Michelle, Fowler, Nathan, Nastoupil, Loretta, Feng, Lei, Loyer, Evelyn, Younes, Anas
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5279071/
https://ncbi.nlm.nih.gov/pubmed/25039868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13014
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items